The introduction of new therapies into clinical practice raises a number of problems, both ethical and scientific. Patients accept, and clinicians administer, experimental treatments in the hope of therapeutic benefit. However, retrospective analyses indicate that the chances of achieving this aim are slim. For example, data from 187 phase I studies on 54 drugs revealed an objective response rate of only 4.2% (Estey et al., 1986) . Set against the limited potential for therapeutic benefit in a phase I study is the likelihood of toxicity, the aims of a phase I study including the definition of the maximum tolerated dose (MTD) and the detailing of adverse side effects (Von Hoff et al., EORTC New Drug Development Committee, 1985) . Thus it falls upon all those involved to ensure that phase I studies enrol the minimum number of patients and that the maximum possible amount of information is derived from them.
To allow the MTD of a new drug to be defined with reasonable safety phase I studies involve dose escalation. However, this introduces an additional complication. Patients treated at the lower end of the dose escalation strategy are unlikely to receive even a potentially therapeutic dose since most cytotoxic drugs are only active at or near the MTD. The need to initiate phase I studies at what is predicted to be a non-toxic dose is a reflection of the disparity between the MTD of cytotoxic drugs in experimental animals and their MTD in patients. If the MTD was the same in patients and experimental animals, in every case, dose escalation strategies would not be required and all patients could be treated directly at the highest dose that could be safely given. Retrospective analyses of results with 64 cytotoxic drugs shows that, with only a few exceptions, the ratio of the MTD in humans and, for example, the LDIo in mice falls within the range 0.1-10 (Freireich et al., 1986; Homan, 1972; Goldsmith et al., 1975; Penta et al., 1979; Rozencweig et al., 1981; Grieshaber & Marsoni, 1986; Collins et al., 1986 Collins and co-workers at the National Cancer Institute, USA made a major contribution to the field of experimental cancer chemotherapy when, in 1986, they analysed the reasons for the disparity between the MTD of cytotoxic drugs in patients and their LD1O in mice (Collins et al., 1986) .
In so doing they identified two sets of inter-species variables, i.e. pharmacokinetic and pharmacodynamic. Pharmacodynamic variables relate to target cell sensitivity which may be influenced by drug uptake, intracellular metabolism, interaction with target macromolecules and efflux from the Received 14 August 1989; and in revised form 19 September 1989. cell. Pharmacokinetic variables include the whole body absorption, distribution, metabolism and excretion of the agent. These pharmacokinetic factors all impinge upon the levels of active compound, either parent drug or metabolite, to which the target cell is exposed and their overall effect in vivo is reflected in the area under the plasma drug concentration versus time curve (AUC or C x T -concentration x time).
In (Smith et al., 1988; Frank et al., 1989; Hantel et al., 1988; Ames & Loprinzi, 1988; Graham et al., 1989; Foster et al., 1988; Gianni et al., 1989) . Although it is still too early to comment on the overall value of the approach certain lessons have already been learnt which should help to focus future studies. The first lesson relates to the simple but fundamental issue of assay sensitivity. If the drug assay is not sensitive enough the levels at the phase I starting dose cannot be measured and hence calculations on the difference between the mouse LDIo and phase I starting dose AUC cannot be performed. Problems of assay sensitivity have been encountered with two compounds; amphethinile (Smith et al., 1988) and oxantrazole (Frank et al., 1989; Hantel et al., 1988; Ames & Loprinzi, 1988) . The second area where difficulty has been encountered in the prospective application of pharmacokinetically guided dose escalation relates to inter patient variability in pharmacokinetics. Thus in the phase I study of the anthrapyrazole C1941 the AUC variation at the phase I starting dose was 3-fold and this precluded the use of AUC values in dose escalation calculations (Foster et al., 1988) . This problem might have been foreseen since there is already ample evidence of inter patient pharmacokinetic variability in the literature. The challenge in such cases is to identify the cause of the variation and compensate for it when calculating doses. Carboplatin is a recent example of how this can be done (Egorin et al., 1984; Calvert et al., 1990) . Finally, the use of AUC values to guide dose escalation runs into further problems when inter species differences in pharmacokinetics are particularly marked. Thus attempts by Gianni and co-workers to use pharmacokinetics to guide dose escalation in the phase I study of 4'-deoxy-4'-iododoxorubicin were frustrated by pronounced inter species differences in both metabolism (to an active species) and protein binding (Gianni et al., 1989) .
As in any field of scientific endeavour, these problems should be greeted as opportunities to learn. Initial experience of attempts to apply preclinical pharmacokinetic information to phase I studies has identified or emphasised areas of weakness which in future studies should be addressed more carefully. Once this is done it should be possible to improve the efficiency of phase I studies thereby reducing resource input, both patient and clinical, and providing answers more rapidly.
Although the use of pharmacokinetic information has been identified as one possible approach to improving phase I studies with cytotoxic drugs, the challenge for the future is to enhance the pharmacodynamic component of early clinical trials. Clinical methods of monitoring pharmacodynamics are now highly sophisticated and continue to improve in their accuracy and sensitivity, notable recent advances being the introduction ofCT and NMR scanning. However, pharmacodynamic studies at the cellular or molecular level remain infrequent components of phase I studies despite the fact that without them no firm conclusion can be reached as to the utility of the target the new therapy is designed to exploit. For too long such mechanistic data have been placed in the category of non-essential information and, if at all, they have only been accrued after the drug has entered routine clinical use. With the advent of powerful techniques such as immunological methods of detecting drug induced damage, flow cytometric determination of cellular drug effects and the non-invasive measurement of tumour metabolism by NMR spectroscopy, pharmacodynamic studies at the molecular and cellular level can be performed in patients. It is particularly important that this should be done in the phase I trial as this is the first, and possibly the last, time that the treatment is given to humans and hence it is critical that the maximum possible amount of information is derived as quickly as possible.
For the first time in cancer chemotherapy it is now possible to study both sides of the pharmacological coin in the clinical setting. By the combined application ofpharamacodynamic and pharmacokinetic studies in phase I investigations it should be possible to reduce simultaneously the resources required and maximise the benefit obtained. In addition, the improved application of pharmacokinetic and pharmacodynamic studies should allow the more rapid and more rational evaluation of new therapies and this in turn must enhance the prospects for improved cancer treatment.
